Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07006025 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
A Phase 1 study of MDS, sponsored by Treebough Therapies.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07006025 is a Phase 1 study of MDS that is actively recruiting participants, run by Treebough Therapies. The registered enrollment target is 20 participants, below the 96-participant average among 22 other MDS trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07006025, a Phase 1 study of MDS, is actively recruiting participants, sponsored by Treebough Therapies.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with relapsed or refractory myelodysplastic syndrome. The main questions it aims to answer are: * Does the combination drug exhibit hematological and nonhematological toxicity? * Does the combination drug improve health status and reduce the number of days of hospitalization? Participants will: * Take tetrahydrouridine and decitabine once a week for 24 weeks * Visit the clinic once every 4 weeks for checkups and tests * Keep a diary of their symptoms
Conditions Studied
Interventions
- DRUG Decitabine
Study Locations (1)
New York
- Montefiore Einstein Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07006025
The ClinicalTrials.gov registry entry for NCT07006025 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 22 other MDS trials with a reported enrollment target (79% lower). The listed sponsor is Treebough Therapies, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with MDS appearing as the primary indexed condition, and to 1 intervention - of which Decitabine is the first listed.
NCT07006025 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07006025 about?
NCT07006025 is a clinical study titled "A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)". The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with relapsed or refractory myelodysplastic syndrome. The main questions it aims to answer are: * Does the combination drug exhibit h...
What is the current status of trial NCT07006025?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-03. Estimated completion is 2027-03-30.
What conditions does trial NCT07006025 study?
This clinical trial studies the following conditions: MDS.
What interventions are being tested in trial NCT07006025?
The interventions under investigation include: Decitabine (DRUG).
Who is sponsoring clinical trial NCT07006025?
This trial is sponsored by Treebough Therapies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07006025 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
-
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.